Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT02035293
Last Updated: 2017-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
750 participants
INTERVENTIONAL
2014-01-08
2017-10-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PEP
No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
PEP
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PEP
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COPD previously diagnosed
Exclusion Criteria
* Creatinine clearance \< 30 mL / min
* Patient hospitalized for exacerbation of COPD for more than 48 hours
* Pneumothorax
* Exams impossible to be performed
* Pregnancy
* Life expectancy \< 3 months
* Patients already receiving anticoagulant therapy for another reason (mechanical valve, cardiac arrhythmia).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francis COUTURAUD, PU-PH
Role: PRINCIPAL_INVESTIGATOR
CHRU de Brest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU
Angers, , France
CHRU de Brest
Brest, , France
HIA
Brest, , France
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Hôpital Européen Georges Pompidou
Paris, , France
CH de Cornouaille Quimper
Quimper, , France
Hôpital Nord
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RB 13-087 [CHRU Brest]
Identifier Type: -
Identifier Source: secondary_id
PEP
Identifier Type: -
Identifier Source: org_study_id